With First Advertising Letter In 12 Months, US FDA Goes After Xeris’s Webpage Promotion Of Recorlev

 
• By Brenda Sandburg
Ad online
FDA objects to Recorlev promotional claims on webpage for the Cushing's syndrome drug • Source: Shutterstock

More from Marketing & Advertising

More from Compliance